Stock Analiz

LENSAR, Inc. LNSR

Medical/Dental Instruments · data as of November 13, 2026

$5.00Market cap $61M
Open the interactive analysis →

LENSAR, Inc. (LNSR) is a healthcare company listed in the US with a market value of about $61M. In the twelve months to September 30, 2026 it had revenue of $60M and net income of $34M, a net margin of 56.1%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 1.8, 5-year revenue growth of 17% a year, a 5-year average ROIC of -50%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 4% above the current price.

About LENSAR

LENSAR is listed in the US and classified in medical/dental instruments. Revenue went from $31M in 2019 to $58M in 2025, growth of about 11.4% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 18% over three years (dilution for shareholders). It spends 10% of revenue on research and development.

Score: 1.6 / 5

Value3/5
Future growth2/5
Track record2/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)1.8
Forward P/E—
P/FCF—
P/S1.0
P/B5.6
EV/EBITDA21.0
PEG—
Dividend yield0.00%
FCF yield-7.8%
Shareholder yield0.0%
Intrinsic value vs. price+4%

Growth and quality

Revenue growth (1 yr)9.2%
Revenue growth (5 yrs, per year)17.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-52.9%
ROIC (5-yr avg.)-50.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$60M$58M$53M$42M$35M$34M$26M$31M
Net income$34M-$34M-$31M-$14M-$20M-$20M-$20M-$15M
Free cash flow-$5M-$15M-$2M-$10M-$15M-$9M-$14M-$13M
EPS (diluted)$2.72$-2.87$-2.73$-1.31$-1.96$-2.09$-4.28$-13.70
Net margin56.1%-58.7%-58.7%-34.1%-56.3%-56.9%-75.0%-48.0%
ROIC——-112.7%-27.0%-35.6%-26.7%-20.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is LENSAR’s P/E ratio?

About 1.8, based on the last twelve months of diluted earnings per share.

Is LENSAR stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 4% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does LENSAR pay a dividend?

Not currently.

Is LENSAR a good stock to buy?

We do not give buy or sell advice. LENSAR scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.